Long term outcomes of patients with advanced/unresectable melanoma treated with immune checkpoint inhibitors

被引：0
|
作者：
Sonke, Eric
Angeles, Arkhjamil
Nguyen, Thao Phuong
Bahl, Gaurav
Poon, Vincent Isaac
Bernstein, Vanessa
Weppler, Alison Margaret
Savage, Kerry J.
机构：
[1] BC Canc, Vancouver, BC, Canada
[2] BC Canc, Abbotsford, BC, Canada
[3] BC Canc Agcy Vancouver Isl Ctr, Victoria, BC, Canada
[4] BCCA, Vancouver Ctr, Vancouver, BC, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21518
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Estimating long-term survivorship in patients with advanced melanoma treated with immune-checkpoint inhibitors: Analyses from the phase III CheckMate 067 trial
    Mohr, P.
    Larkin, J.
    Paly, V. F.
    Azocar, A. Remiro
    Baio, G.
    Kurt, M.
    Amadi, A.
    Rizzo, J. I.
    Johnson, H. M.
    Moshyk, A.
    Kotapati, S.
    Middleton, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S747 - S747
  • [32] Long-Term Outcomes of Immune Checkpoint Inhibition in Metastatic Melanoma
    Aroldi, Francesca
    Middleton, Mark R.
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2022, 23 (03) : 331 - 338
  • [33] Vitiligo is correlated with clinical benefits in patients with advanced cutaneous melanoma treated with immune checkpoint inhibitors (ICI).
    Reinas, Gaston Martin
    Muino, Marcelo
    Abal, Mariana
    Gerardi, Carlos Garcia
    Tognelli, Flavio
    Deza, Ernesto Gil
    Gonzalez, Cesar
    Gonzalez, Liliana D.
    Nunell, Marcelo Andres
    Ordonez, Alba Marin
    Morgenfeld, Eduardo L.
    Rivarola, Edgardo G. J.
    Gercovich, Felipe G.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [34] Association between immune-related adverse events and long-term survival outcomes in patients treated with immune checkpoint inhibitors
    Maillet, Denis
    Corbaux, Pauline
    Stelmes, Jean-Jacques
    Dalle, Stephane
    Locatelli-Sanchez, Myriam
    Perier-Muzet, Marie
    Duruisseaux, Michael
    Kiakouama-Maleka, Lize
    Freyer, Gilles
    Boespflug, Amlie
    Peron, Julien
    EUROPEAN JOURNAL OF CANCER, 2020, 132 : 61 - 70
  • [35] Obesity and cancer outcomes among patients with lung cancer and cutaneous melanoma treated with immune checkpoint inhibitors and EGFR inhibitors
    Nduaguba, Sabina O.
    Hazlehurst, Lori
    CANCER RESEARCH, 2024, 84 (06)
  • [36] Evaluation of the modified immune prognostic index to prognosticate outcomes in metastatic uveal melanoma patients treated with immune checkpoint inhibitors
    Sander, Michael
    Stukalin, Igor
    Vallerand, Isabelle A.
    Goutam, Siddhartha
    Ewanchuk, Benjamin W.
    Meyers, Daniel E.
    Pabani, Aliyah
    Morris, Don
    Heng, Daniel Y. C.
    Cheng, Tina
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB170 - AB170
  • [37] Evaluation of the modified immune prognostic index to prognosticate outcomes in metastatic uveal melanoma patients treated with immune checkpoint inhibitors
    Sander, Michael S.
    Stukalin, Igor
    Vallerand, Isabelle A.
    Goutam, Siddhartha
    Ewanchuk, Benjamin W.
    Meyers, Daniel E.
    Pabani, Aliyah
    Morris, Don G.
    Heng, Daniel Y. C.
    Cheng, Tina
    CANCER MEDICINE, 2021, 10 (08): : 2618 - 2626
  • [38] Long term outcome of complete responders to immune checkpoint inhibitors (ICI) or target therapy (TT) in advanced melanoma
    Boutros, C.
    Belkadi-Sadou, D.
    Archambaud, B.
    Vallet, A.
    Dutheil, A.
    Marchand, A.
    Roy, S.
    Routier, E.
    Robert, C.
    ANNALS OF ONCOLOGY, 2023, 34 : S672 - S673
  • [39] Hyperprogressive disease in patients with advanced cancer treated with immune checkpoint inhibitors
    Sen, Gulin Alkan
    Oztas, Nihan Senturk
    Degerli, Ezgi
    Guliyev, Murad
    Can, Guenay
    Turna, Hande
    Ozguroglu, Mustafa
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (12): : 3264 - 3271
  • [40] Navigating the landscape of immune checkpoint inhibitors and novel immunotherapies in melanoma: long-term outcomes, progress, and challenges
    Cheruvu, Sowmya
    Mcmahon, David
    Larkin, James
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2025, 25 (03) : 245 - 256
12345